Fondaparinux and idraparinux prolonged coagulation times in the PiCT, Heptest, and chromogenic FXa assays in a dose-dependent manner in pooled human normal plasma.
Does the prothrombinase-induced clotting time (PiCT) assay accurately measure the anticoagulant effects of fondaparinux and idraparinux in human plasma?
PiCT is a suitable assay to determine the anticoagulant effects of the new FXa inhibitors fondaparinux and idraparinux.
Prothrombinase-induced clotting time (PiCT) determines the anticoagulant effects of heparins, low molecular weight heparins (LMWHs), and direct thrombin inhibitors. At present, this is the only method that measures the effects of all of these inhibitors, in contrast to the prothrombin time, activated partial thromboplastin time (aPTT), Heptest, ecarin clotting time, and the chromogenic assays. The antithrombin-dependent direct factor (F) Xa inhibitors fondaparinux and idraparinux were compared with the LMWH dalteparin on PiCT, aPTT, Heptest, and chromogenic anti-FXa assays in pooled human normal plasma samples. Fondaparinux and idraparinux prolonged the coagulation times in the PiCT, Heptest, and chromogenic FXa assays in a dose-dependent manner, in contrast to the aPTT. We conclude that PiCT is a suitable assay to determine the anticoagulant effects of these two new FXa inhibitors in patients receiving treatment with these compounds.
Harenberg et al. (Sun,) reported a other. Fondaparinux and idraparinux vs. Dalteparin was evaluated on Coagulation times. Fondaparinux and idraparinux prolonged coagulation times in the PiCT, Heptest, and chromogenic FXa assays in a dose-dependent manner in pooled human normal plasma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: